Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Total Liabilities (2016 - 2025)

Fortress Biotech has reported Total Liabilities over the past 13 years, most recently at $123.4 million for Q4 2025.

  • Quarterly results put Total Liabilities at $123.4 million for Q4 2025, down 15.43% from a year ago — trailing twelve months through Dec 2025 was $123.4 million (down 15.43% YoY), and the annual figure for FY2025 was $123.4 million, down 15.43%.
  • Total Liabilities for Q4 2025 was $123.4 million at Fortress Biotech, up from $116.2 million in the prior quarter.
  • Over the last five years, Total Liabilities for FBIO hit a ceiling of $244.3 million in Q4 2022 and a floor of $116.2 million in Q3 2025.
  • Median Total Liabilities over the past 5 years was $167.3 million (2023), compared with a mean of $173.6 million.
  • Biggest five-year swings in Total Liabilities: surged 63.17% in 2021 and later tumbled 32.07% in 2023.
  • Fortress Biotech's Total Liabilities stood at $170.6 million in 2021, then surged by 43.16% to $244.3 million in 2022, then plummeted by 32.07% to $165.9 million in 2023, then decreased by 12.1% to $145.9 million in 2024, then fell by 15.43% to $123.4 million in 2025.
  • The last three reported values for Total Liabilities were $123.4 million (Q4 2025), $116.2 million (Q3 2025), and $122.5 million (Q2 2025) per Business Quant data.